Search

Your search keyword '"Ngabo, Didier"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Ngabo, Didier" Remove constraint Author: "Ngabo, Didier"
30 results on '"Ngabo, Didier"'

Search Results

1. Publisher Correction: Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab′)2 fragments

2. Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab′)2 fragments

3. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

4. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

5. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

6. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

7. The Omicron Sub-Variant BA.4 Displays a Remarkable Lack of Clinical Signs in a Golden Syrian Hamster Model of SARS-CoV-2 Infection

8. Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant

9. SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal Inoculum

10. Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015

11. Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab′)2 fragments.

12. Unique human immune signature of Ebola virus disease in Guinea

13. Infection‐competent monkeypox virus contamination identified in domestic settings following an imported case of monkeypox into the UK

15. Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa

17. Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins

18. Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant

19. Real-time, portable genome sequencing for Ebola surveillance

20. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19

21. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

22. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model

23. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

24. Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model

25. Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19

26. Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge

27. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

30. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Catalog

Books, media, physical & digital resources